ClinicalTrials.gg
CompletedNCT01744665ENESTgoalUpdated Mar 10, 2020Results posted

A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation

A Phase 2 interventional study of nilotinib in CML, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
31st of 66
59 · median 55
Started
2013
with 10 others
Phase 2
25 of 66
1 open now
Registered
40th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 31st largest by enrollment, is one of 11 that started in 2013, is one of 25 in phase 2, and was the 40th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in patients who achieve MR4.5

Read the detailed description

Study protocol included criteria for study termination that was met when > 2 patients lost CCyR during TFR phase (> 1% BCR-ABL); This study was terminated early as > 2 cases of confirmed loss of complete cytogenetic response were reported despite BCR-ABL monitoring during the TFR Phase. All cases achieved MR4.5 after Nilotinib treatment re-initiation and maintained until end of study; trial did not mandate re-initiation within 4 weeks after loss of MMR_ that was a requirement in other Nilotinib TFR trials Initial sample size was 300 patients with CML-CP; Amendment #2 in June 2015 reduced sample size to 59 due to recruitment challenges; Study endpoint analysis and interpretations of data were challenging due to small sample size for early study closure..

03

Conditions studied

  • CML

Keywords

  • CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of CML
  • Treated with at least 1 year of imatinib
  • Bcr-Abl level by PCR must be less than or equal to 0.1% and greater than 0.0032% by PCR reported on the International scale confirmed during screening
  • Written obtained prior to any screening procedures performed

Exclusion criteria

Exclusion Criteria:

  • T315I mutation
  • Prior imatinib failure or had accelerated phase or blast crisis CML
  • Impaired cardiac function
  • Pregnant or lactating women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Treatment Free Remission

    Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.

    Drug: nilotinib

Interventions

  • Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Without Molecular Relapse Within 6 Months After Starting the TFR Phase

    Percentage of particpants without confirmed loss of MMR within 6 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4, in the first 6 months after starting nilotinib TFR phase by the number of patients who entered nilotinib TFR phase. Molecular relapse is defined as having a confirmed BCR-ABL ratio above MMR (2 consecutive BCR-ABL levels \>0.1% IS taken approximately 4 weeks apart).

    Time frame: 6 months after stopping nilotinib therapy

Secondary outcomes

  1. Relapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5).

    Relapse-free survival after the start of the TFR phase was summarized using the product-limit (Kaplan-Meier) estimates. The median for the relapse free survival and its 95% confidence intervals were provided. This analysis was performed on the FAS. Patients who dropped out without relapse were treated as censored observations.

    Time frame: 7 years

  2. Percentage of Participants Without Molecular Relapse Within 12 and 24 Months After Starting the Treatment -Free Remission (TFR) Phase

    The percentage of participants without confirmed loss of MRR at 12 and 24 months is calculated by dividing the number of patients with no documented confirmed loss of MR4 at 12 and 24 months after starting the nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.

    Time frame: 12 and 24 months after starting the TFR

  3. Percentage of Participants Who Regained MR4.5 After Restarting Nilotinib Due to Molecular Relapse

    The percentage of participants who regained MR4.5 after restarting nilotinib will be calculated as the number of patients who achieved MR4.5 after having lost MR4 divided by the number of patients who lost MR4.

    Time frame: Restart of nilotinib up to month 6, 12 and 24

  4. Number of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause.

    Progression to AP/BC and death where the "failure" event is the earliest occurrence of the following event: progression to AP/BC date.

    Time frame: Baseline up to approximately 5 years

  5. Overall Survival (OS)

    OS was defined as the time from the date of cessation of nilotinib therapy to the date of death from any cause.

    Time frame: Baseline up to approximately 5 years

  6. Change in Symptom-burden Scores by the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Assessment

    The M.D. Anderson Symptom Inventory for CML patients (MDASI-CML) was used to assess the nature and impact of symptom burden on life. It consisted of 20 validated symptom items and 6 validated interference items. Each item was assessed on an 11 point scale with responses from 0-10, 0=not present and 10=as bad as you can imagine. Symptom score (SS) was calculated when a patient scored at least 8 items of the symptom items using the formula: (sum of scores for the items answered) / number of items answered. If a subject responded to \< 8 symptom items, the score was considered missing. Interference score (IS) was calculated when a patient scored at least 4 items using the formula: (sum of scores for the items answered)/number of items answered. If a subject responded to \< 4 interference items, the score was considered missing. The total symptom score was 0-200 and total interference score was 0-60. Mean change from baseline was summarized at all post-baseline time points

    Time frame: From baseline to time to when MR4.5 is confirmed, up to 24 months, and from end of Consolidation Phase to 6 and 12 months into the TFR Phase

  7. Change in Health Utility Assessed by EuroQol Group-5D-3L (EQ-5D-3L) Visual Analogue - Safety Set

    The EQ-5D-3L questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).

    Time frame: From baseline to time to when MR4.5, up to 24 months, is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase

  8. Change in Observed Scores for Patient Quality of Life Assessed by SF-8 - Safety Set

    The SF-8 questionnaire consisted of 8 items (general health, physical functioning, role physical, bodily pain, vitality, social functioning, role-emotional and mental health) and was used to assess the impact of nilotinib treatment discontinuation on the quality of life. Each item had a 1 to 5 or 1 to 6 point response range and the higher number in the raw scores indicated poorer quality of life. The physical and mental component summary measures were calculated using a norm-based scoring method given in the instrument guidelines. These norm-based scores were summarized at baseline and mean change from baseline for post-baseline time points. The norm-based scores (based on the US population) had a mean of 50 and standard deviation of 10. Higher norm-based summary scores indicated better health

    Time frame: From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase

  9. Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 3 in Consolidation Phase - Safety Set

    The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

    Time frame: At month 3 in Consolidation Phase

  10. Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Consolidation Phase - Safety Set

    The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

    Time frame: Month 12 in Consolidation Phase

  11. Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 24 in Consolidation Phase - Safety Set

    The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

    Time frame: Month 24 in Consolidation Phase

  12. Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 6 in Treatment Free Remission Phase - Safety Set

    The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

    Time frame: Month 6 in in Treatment Free Remission Phase

  13. Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Treatment Free Remission Phase - Safety Set

    The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

    Time frame: Month 12 in in Treatment Free Remission Phase

07

Results

Posted Mar 10, 2020

Participant flow

Monitoring Phase
Participant flow — Monitoring Phase
MilestoneNilotinib
Started59
Completed41
Not completed18
Withdrew: Adverse event4
Withdrew: Abnormal laboratory value(s)1
Withdrew: Unsatisfactory therapeutic effect7
Withdrew: Withdrawal by subject5
Withdrew: Did not achieve mr4.51
Consolidation Phase
Participant flow — Consolidation Phase
MilestoneNilotinib
Started41
Completed22
Not completed19
Withdrew: Adverse event2
Withdrew: Unsatisfactory therapeutic effect4
Withdrew: Withdrawal by subject4
Withdrew: Administrative problems9
Treatment Free Remission Phase
Participant flow — Treatment Free Remission Phase
MilestoneNilotinib
Started32
Completed32
Not completed0
Re-initiation Phase
Participant flow — Re-initiation Phase
MilestoneNilotinib
Started17
Completed4
Not completed13
Withdrew: Administrative problems10
Withdrew: Adverse event1
Withdrew: No longer required treatment1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants Without Molecular Relapse Within 6 Months After Starting the TFR Phase

Percentage of particpants without confirmed loss of MMR within 6 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4, in the first 6 months after starting nilotinib TFR phase by the number of patients who entered nilotinib TFR phase. Molecular relapse is defined as having a confirmed BCR-ABL ratio above MMR (2 consecutive BCR-ABL levels \>0.1% IS taken approximately 4 weeks apart).

Time frame:
6 months after stopping nilotinib therapy
Reported as:
Count of participants · Participants
Percentage of Participants Without Molecular Relapse Within 6 Months After Starting the TFR Phase
ParticipantsTreatment Free Remission
Number of participants12
SecondaryRelapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5).

Relapse-free survival after the start of the TFR phase was summarized using the product-limit (Kaplan-Meier) estimates. The median for the relapse free survival and its 95% confidence intervals were provided. This analysis was performed on the FAS. Patients who dropped out without relapse were treated as censored observations.

Time frame:
7 years
Reported as:
Median · weeks
Relapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5).
weeksTreatment Free Remission
Relapse Free Survival is Defined as Time From the Date of Nilotinib Treatment Discontinuation to the First Documented Molecular Relapse (Confirmed Loss of MR4.5).21.4 (17.1 to NA)
SecondaryPercentage of Participants Without Molecular Relapse Within 12 and 24 Months After Starting the Treatment -Free Remission (TFR) Phase

The percentage of participants without confirmed loss of MRR at 12 and 24 months is calculated by dividing the number of patients with no documented confirmed loss of MR4 at 12 and 24 months after starting the nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.

Time frame:
12 and 24 months after starting the TFR
Reported as:
Count of participants · Participants
Percentage of Participants Without Molecular Relapse Within 12 and 24 Months After Starting the Treatment -Free Remission (TFR) Phase
ParticipantsTreatment Free Remission
Month 12 — Number of participants8
Month 24 — Number of participants2
SecondaryPercentage of Participants Who Regained MR4.5 After Restarting Nilotinib Due to Molecular Relapse

The percentage of participants who regained MR4.5 after restarting nilotinib will be calculated as the number of patients who achieved MR4.5 after having lost MR4 divided by the number of patients who lost MR4.

Time frame:
Restart of nilotinib up to month 6, 12 and 24
Reported as:
Count of participants · Participants
Percentage of Participants Who Regained MR4.5 After Restarting Nilotinib Due to Molecular Relapse
ParticipantsTreatment Free Remission
Month 6 — Number of participants7
Month 12 — Number of participants17
Month 24 — Number of participants17
SecondaryNumber of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause.

Progression to AP/BC and death where the "failure" event is the earliest occurrence of the following event: progression to AP/BC date.

Time frame:
Baseline up to approximately 5 years
Reported as:
Number · participants
Number of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause.
participantsTreatment Free Remission
Number of Participants Who Progressed to Accelerated Phase/Blastic Crisis (AP/BC) or Died From From Any Cause.0
SecondaryOverall Survival (OS)

OS was defined as the time from the date of cessation of nilotinib therapy to the date of death from any cause.

Time frame:
Baseline up to approximately 5 years
Reported as:
Number · participants
Overall Survival (OS)
participantsTreatment Free Remission
Overall Survival (OS)0
SecondaryChange in Symptom-burden Scores by the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Assessment

The M.D. Anderson Symptom Inventory for CML patients (MDASI-CML) was used to assess the nature and impact of symptom burden on life. It consisted of 20 validated symptom items and 6 validated interference items. Each item was assessed on an 11 point scale with responses from 0-10, 0=not present and 10=as bad as you can imagine. Symptom score (SS) was calculated when a patient scored at least 8 items of the symptom items using the formula: (sum of scores for the items answered) / number of items answered. If a subject responded to \< 8 symptom items, the score was considered missing. Interference score (IS) was calculated when a patient scored at least 4 items using the formula: (sum of scores for the items answered)/number of items answered. If a subject responded to \< 4 interference items, the score was considered missing. The total symptom score was 0-200 and total interference score was 0-60. Mean change from baseline was summarized at all post-baseline time points

Time frame:
From baseline to time to when MR4.5 is confirmed, up to 24 months, and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Reported as:
Mean · scores on a scale
Change in Symptom-burden Scores by the M.D. Anderson Symptom Inventory - Chronic Myeloid Leukemia (MDASI-CML) Assessment
scores on a scaleTreatment Free Remission
SS Baseline (observed value), n=400.125 ± 0.1314
SS Consolidation Ph - M 3 (change from BL) n=260.012 ± 0.1362
SS Consolidation Ph - M 12 (change from BL) n=300.021 ± 0.1140
SS Consolidation Ph - M 24 (change from BL) n=260.026 ± 0.1402
SS TFR Baseline (observed value) n=320.160 ± 0.1496
SS TFR - Month 6 (change from BL) n=10-0.005 ± 0.1773
SS TFR - Month 12 (change from BL) n=5-0.032 ± 0.1034
IS Baseline (observed value), n=400.123 ± 0.2156
IS Consolidation Ph - M 3 (change from BL) n=250.008 ± 0.1911
IS Consolidation Ph - M 12 (change from BL) n=30-0.005 ± 0.1983
IS Consolidation Ph - M 24 (change from BL) n=260.015 ± 0.1942
IS TFR Baseline (observed value) n=320.141 ± 0.2067
IS TFR - Month 6 (change from BL) n=10-0.015 ± 0.1780
IS TFR - Month 12 (change from BL) n=5-0.037 ± 0.1880
SecondaryChange in Health Utility Assessed by EuroQol Group-5D-3L (EQ-5D-3L) Visual Analogue - Safety Set

The EQ-5D-3L questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state).

Time frame:
From baseline to time to when MR4.5, up to 24 months, is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Reported as:
Median · scores on scale
Change in Health Utility Assessed by EuroQol Group-5D-3L (EQ-5D-3L) Visual Analogue - Safety Set
scores on scaleTreatment Free Remission
Baseline (observed value)83.250 (4.50 to 100.00)
Consolidation Ph - M 3 (change from BL)2.000 (-50.00 to 87.00)
Consolidation Ph - M 12 (change from BL)3.250 (-75.00 to 82.00)
Consolidation Ph - M 24 (change from BL)1.350 (-30.00 to 85.50)
TFR Baseline (observed value)80.00 (9.35 to 100.00)
TFR - Month 6 (change from BL)10.00 (-30.00 to 89.65)
TFR - Month 12 (change from BL)0.000 (-20.00 to 35.00)
SecondaryChange in Observed Scores for Patient Quality of Life Assessed by SF-8 - Safety Set

The SF-8 questionnaire consisted of 8 items (general health, physical functioning, role physical, bodily pain, vitality, social functioning, role-emotional and mental health) and was used to assess the impact of nilotinib treatment discontinuation on the quality of life. Each item had a 1 to 5 or 1 to 6 point response range and the higher number in the raw scores indicated poorer quality of life. The physical and mental component summary measures were calculated using a norm-based scoring method given in the instrument guidelines. These norm-based scores were summarized at baseline and mean change from baseline for post-baseline time points. The norm-based scores (based on the US population) had a mean of 50 and standard deviation of 10. Higher norm-based summary scores indicated better health

Time frame:
From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase
Reported as:
Mean · scores on a scale
Change in Observed Scores for Patient Quality of Life Assessed by SF-8 - Safety Set
scores on a scaleTreatment Free Remission
Baseline50.508 ± 8.4313
Consolidation Ph - M 350.720 ± 7.6047
Consolidation Ph - M 1249.020 ± 10.1851
Consolidation Ph - M 2447.648 ± 8.7416
TFR Baseline48.382 ± 8.6503
TFR - Month 646.605 ± 9.5042
TFR - Month 1246.006 ± 8.6997
SecondaryPercentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 3 in Consolidation Phase - Safety Set

The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

Time frame:
At month 3 in Consolidation Phase
Reported as:
Count of participants · Participants
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 3 in Consolidation Phase - Safety Set
ParticipantsNo ProblemsSome ProblemsExtreme Problems
Mobility — Number of participants2240
Self-Care — Number of participants2510
Usual Activities — Number of participants2150
Pain/Discomfort — Number of participants12130
Anxiety / Depresssion — Number of participants2060
SecondaryPercentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Consolidation Phase - Safety Set

The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

Time frame:
Month 12 in Consolidation Phase
Reported as:
Count of participants · Participants
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Consolidation Phase - Safety Set
ParticipantsNo ProblemsSome ProblemsExtreme Problems
Mobility — Number of participants2380
Self-Care — Number of participants3100
Usual Activities — Number of participants2371
Pain/Discomfort — Number of participants18111
Anxiety / Depresssion — Number of participants21100
SecondaryPercentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 24 in Consolidation Phase - Safety Set

The EuroQol Five Dimensional Three-level (EQ-5D-3L) questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

Time frame:
Month 24 in Consolidation Phase
Reported as:
Count of participants · Participants
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 24 in Consolidation Phase - Safety Set
ParticipantsNo ProblemsSome ProblemsExtreme Problems
Mobility — Number of participants1980
Self-Care — Number of participants2800
Usual Activities — Number of participants2340
Pain/Discomfort — Number of participants1792
Anxiety / Depresssion — Number of participants1980
SecondaryPercentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 6 in Treatment Free Remission Phase - Safety Set

The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

Time frame:
Month 6 in in Treatment Free Remission Phase
Reported as:
Count of participants · Participants
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 6 in Treatment Free Remission Phase - Safety Set
ParticipantsNo ProblemsSome ProblemsExtreme Problems
Mobility — Number of participants730
Self-Care — Number of participants1000
Usual Activities — Number of participants1000
Pain/Discomfort — Number of participants541
Anxiety / Depresssion — Number of participants820
SecondaryPercentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Treatment Free Remission Phase - Safety Set

The EuroQol Five Dimensional Three-level questionnaire (EQ-5D-3L) comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item has 3 levels (no problems, some problems and extreme problems). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized at each time point

Time frame:
Month 12 in in Treatment Free Remission Phase
Reported as:
Count of participants · Participants
Percentage of Participants' Scores at Each Level Assessed by EQ-5D-3L for Month 12 in Treatment Free Remission Phase - Safety Set
ParticipantsNo ProblemsSome ProblemsExtreme Problems
Mobility — Number of participants410
Self-Care — Number of participants500
Usual Activities — Number of participants410
Pain/Discomfort — Number of participants140
Anxiety / Depresssion — Number of participants320

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment or last day in TFR Phase up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/59 (0%)19/59 (32.2%)59/59 (100%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventNilotinib
Abdominal painGastrointestinal disorders2/59
Cardiac failureCardiac disorders1/59
Coronary artery diseaseCardiac disorders1/59
Myocardial infarctionCardiac disorders1/59
Pericardial effusionCardiac disorders1/59
Hypoaesthesia oralGastrointestinal disorders1/59
Small intestinal obstructionGastrointestinal disorders1/59
Chest discomfortGeneral disorders1/59
Chest painGeneral disorders1/59
Device embolisationGeneral disorders1/59
Most frequent other events
Showing 10 of 57
Most frequent other events
EventNilotinib
FatigueGeneral disorders23/59
ConstipationGastrointestinal disorders17/59
RashSkin and subcutaneous tissue disorders16/59
HeadacheNervous system disorders14/59
ArthralgiaMusculoskeletal and connective tissue disorders12/59
Abdominal painGastrointestinal disorders11/59
NauseaGastrointestinal disorders11/59
Lipase increasedInvestigations11/59
PruritusSkin and subcutaneous tissue disorders11/59
Pain in extremityMusculoskeletal and connective tissue disorders10/59

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall
Mean55.5 ± 12.44
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female13
Male19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Overall
Caucasian25
Black2
Other5
08

Study locations

54 sites
  • University of Alabama Comprehensive Cancer Center University of Alabama (8)
    Birmingham, Alabama 35294, United States
  • Banner MD Anderson Cancer Center Banner MD Anderson (2)
    Gilbert, Arizona 85234, United States
  • Scottsdale Healthcare/TGen Clinical Research Service SC
    Scottsdale, Arizona 85258, United States
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • City of Hope National Medical Center Dept of Oncology
    Duarte, California 91010 3000, United States
  • Compassionate Care Research Group Inc CCCMG
    Fountain Valley, California 92708, United States
  • UC San Diego UC San Diego Cancer Ctr
    La Jolla, California 92093-0987, United States
  • Wilshire Oncology Medical Group Corona Cancer Center
    Multiple Locations, California, United States
  • Epic-Care
    Pleasant Hill, California 94523, United States
  • Sutter Institute for Medical Research Oncology/Hematology
    Sacramento, California 95816-5199, United States
  • St Joseph Heritage Healthcare
    Santa Rosa, California 94503, United States
  • Rocky Mountain Cancer Centers USOR
    Boulder, Colorado 80304, United States
  • Florida Cancer Specialists DeptofFloridaCancerSpecialists
    Fort Myers, Florida 33901, United States
  • MD Anderson Cancer Center - Orlando Cancer Center
    Orlando, Florida 32806, United States
  • H Lee Moffitt Cancer Center and Research Institute H. Lee Moffitt Cancer Ctr (67)
    Tampa, Florida 33612, United States
  • Stroger Cook County Hospital Division of Hematology & Onc
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Iowa Hospitals and Clinics Holden Comprehensive Cancer Ct
    Iowa City, Iowa 52242, United States
  • University of Kansas Hospital and Medical Center Clinical Research Center
    Kansas City, Kansas 66160, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Christus Schumpert Health System
    Shreveport, Louisiana 71101, United States
  • Michigan State University / Breslin Cancer Center Breslin Cancer Center (3)
    Lansing, Michigan, United States
  • Billings Clinic Billings Clinic (8)
    Billings Montana, Montana 59101, United States
  • Hackensack University Medical Center John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Hematology Oncology Associates of Northern New Jersey PA Dept of Hem-Onc of Northern NJ
    Morristown, New Jersey 07962, United States
  • Montefiore Medical Center Montefiore Medicial Center
    Bronx, New York 10467, United States
  • Memorial Sloan Kettering Memorial Sloan Kettering (63)
    New York, New York 10017, United States
  • Weill Cornell Medical Center Dept. of Oncology
    New York, New York 10021, United States
  • Columbia University Medical Center Herbert Irving Pavilion
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Westchester Medical Center NY Medical College
    Valhalla, New York 10595, United States
  • Duke University Medical Center Duke University Med Ctr
    Durham, North Carolina 27710, United States
  • Carolina Oncology Specialists, PC
    Hickory, North Carolina 28602, United States
  • Wake Forest University Health Sciences Hematology and Oncology
    Winston-Salem, North Carolina 27157, United States
  • Ohio State Comprehensive Cancer Center/James Cancer Hospital OSU Medical Center
    Columbus, Ohio 43210, United States
  • Northwest Cancer Specialists Compass Oncology -BKM
    Portland, Oregon 97210, United States
  • University of South Carolina-Hollings Cancer Center Medical University of SC
    Columbia, South Carolina 29203, United States
  • Tennessee Oncology Dept. of Centennial Medical
    Nashville, Tennessee 37203, United States
  • Vanderbilt Univeristy Ingram Cancer Center (10)
    Nashville, Tennessee 37232, United States
  • Hendrick Cancer Center Hendricks Cancer Center
    Abilene, Texas 79601, United States
  • Texas Oncology Texas Oncology - McAllen
    Dallas, Texas 75246, United States
  • Texas Oncology Texas Oncology - Plano West
    Dallas, Texas 75246, United States
  • Texas Oncology P A Texas Oncology - Midland
    Dallas, Texas 75251, United States
  • University of Texas Medical Branch SC
    Galveston, Texas 77555-1188, United States
  • Oncology Consultants Oncology Consultants, P.A.
    Houston, Texas 77024, United States
  • The Methodist Hospital Cornell University
    Houston, Texas 77030, United States
  • South Texas Cancer Center- McAllen
    McAllen, Texas 78503, United States
  • Brooke Army Medical Center Brooke Army Medical
    San Antonio, Texas 78234, United States
  • Waco Cancer and Research Center
    Waco, Texas 76712, United States
  • University of Utah / Huntsman Cancer Institute Huntsman Cancer Center
    Salt Lake City, Utah 84103, United States
  • University of Virginia
    Charlottesville, Virginia 22908, United States
  • Kadlec Clinic Hematology and Oncology SC
    Kennewick, Washington 99336, United States
  • West Virginia University/ Mary Babb Randolph Cancer Center Mary Babb Randolph Cancer Ctr
    Morgantown, West Virginia 26506, United States
  • Medical College of Wisconsin Med College of WI
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Sep 2018, 61 months.

Results were first posted in Mar 2020, 1 year 5 months after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 69. This study's 61 months is above that.

Counting every sponsor, half of 126 studies reached it within 73 months; a quarter within 43 and three quarters within 124.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2012
First posted
Dec 7, 2012
StartActual
Aug 12, 2013
Primary completionActual
Sep 28, 2018
CompletionActual
Sep 29, 2018
Results first posted
Mar 10, 2020
Last update
Mar 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01744665
Responsible party
Sponsor
First posted
Dec 7, 2012
Start date
Aug 12, 2013
Primary completion
Sep 28, 2018
Completion
Sep 29, 2018
Results posted
Mar 10, 2020
Last update
Mar 10, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion